Tenofovir disoproxil fumarate (TDF), marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people.
Tenofovir is also available in a fixed-dose combination with emtricitabine in a product with the brand name Truvada® for once-a-day dosing. (Emtricitabine is marketed as a single-compound product called Emtriva®, also by Gilead.) A fixed-dose triple combination of tenofovir, emtricitabine and efavirenz (Sustiva®, marketed by Bristol-Myers Squibb) is in development.
Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts in controlled studies of tenofovir in treatment-naïve and treatment-experienced adults. There are no study results demonstrating the effect of tenofovir on clinical progression of HIV.
More on [ Tenofovir ]

DrugDigest: Viread (Tenofovir) - Information from DrugDigest on dosage, usage, side effects, interactions, and drug comparisons including generics when available.
Viread - Tenofovir disoproxil fumarate. Product information for US residents and healthcare professionals, including news, FAQs, and information about trials.
Meta Description: [ Viread.com is the official web site for Viread (tenofovir disoproxil fumarate) ]
| Swine Flu Pandemic Build in The United States Of America by Jewish Gilead | |
| Next Video | |